October 05, 2015
A Massachusetts federal judge on Monday divvied out more than $8 million in expenses for a settlement reached between Nexium buyers and Teva Pharmaceutical Industries Ltd., but agreed to hold off on approving fees for AstraZeneca PLC and Ranbaxy Inc. following their win in a multidistrict litigation pay-for-delay trial brought by the same buyers.
September 29, 2015
Nexium buyers who lost at trial in the pay-for-delay multidistrict litigation against AstraZeneca PLC and Ranbaxy Inc. have asked a federal court not to award the drugmakers more than $423,000 in costs, saying it's an issue that would better be decided after appeal.
August 31, 2015
The plaintiffs in the Nexium pay-for-delay multidistrict litigation against AstraZeneca PLC and generic-drug maker Ranbaxy Inc. on Friday appealed to the First Circuit a Massachusetts federal judge's refusal in July to grant them a new trial.
July 30, 2015
A Massachusetts federal judge refused Thursday to let Nexium buyers get a second crack at their pay-for-delay suit against AstraZeneca PLC and Ranbaxy Inc., saying the plaintiffs' claim for how new evidence would let them prove their case at trial was "at least a couple of bridges too far."
June 30, 2015
Plaintiffs in the Nexium pay-for-delay antitrust class action urged a Massachusetts federal court to grant them a new trial Monday because of the Third Circuit's recent Lamictal ruling that reverse payments do not need to include cash.
June 12, 2015
A Massachusetts federal judge on Friday gave tentative approval to a $24 million settlement between Teva Pharmaceutical Industries Ltd. and class action plaintiffs in a pay-for-delay case over generic versions of AstraZeneca PLC's heartburn drug Nexium.
June 04, 2015
Nexium purchasers told a Massachusetts federal court Thursday that the Second Circuit's recent ruling upholding an injunction requiring Actavis PLC to keep an Alzheimer's drug on the market supported their own bid for an injunction in pay-for-delay litigation against Ranbaxy Inc. and AstraZeneca PLC.
April 03, 2015
On the heels of losing a pay-for-delay trial against Ranbaxy Pharmaceuticals Inc. and AstraZeneca PLC over generic Nexium, class plaintiffs contended Thursday that a recent U.S. Food and Drug Administration decision and other developments back their retrial request.
April 02, 2015
Class action plaintiffs in a pay-for-delay case over generic versions of AstraZeneca PLC's heartburn drug Nexium disclosed on Thursday a $24 million settlement freeing Teva Pharmaceutical Industries Ltd. from the case, according to filings in Massachusetts federal court.
March 31, 2015
Ranbaxy Inc. and AstraZeneca PLC urged a Massachusetts federal court Monday to deny a bid by plaintiffs who lost a recent pay-for-delay class action trial over the heartburn drug Nexium to file a supplemental submission, saying it provided no basis for a new trial.